Clinical Trials

06 Nov 2020
- Clinical Trials
- Human Trials
TFF Pharmaceuticals, Felix Biotechnology sign LOI for collaboration, development and licence agreement

By PBR Staff Writer

TFF Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter into a collaboration, development and licence agreement (CDLA).
05 Nov 2020
Clinical Trials
Patient Enrollment
NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer

By PBR Staff Writer

NanOlogy LLC, a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer.
04 Nov 2020
Clinical Trials
Human Trials
GW Pharmaceuticals initiates phase 3 study of Nabiximols for multiple sclerosis-associated spasticity

By PBR Staff Writer

GW Pharmaceuticals along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity.
04 Nov 2020
Clinical Trials
Human Trials
Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen

By PBR Staff Writer

Ionis Pharmaceuticals and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI 70), will evaluate various doses of vupanorsen to inform potential future development.
04 Nov 2020
Clinical Trials
Human Trials
Bristol Myers Squibb’s deucravacitinib meets co-primary endpoints in psoriasis study

By PBR Staff Writer

Bristol Myers Squibb (BMS) announced that its deucravacitinib (BMS-986165) has achieved both co-primary endpoints in the phase 3 psoriasis study.
03 Nov 2020
Clinical Trials
Human Trials
Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease

By PBR Staff Writer

Neuraly announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease.
02 Nov 2020
Clinical Trials
Patient Enrollment
Humanigen announces first patient dosed in phase 3 clinical study of lenzilumab in Covid-19

By PBR Staff Writer

Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first Covid-19 patient with lenzilumab.
30 Oct 2020
Clinical Trials
Human Trials
Humanigen announces first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19

By PBR Staff Writer

Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that the first patient has been dosed at the Emory University School of Medicine in Atlanta, Georgia as part of the in the ACTIV-5 “Big Effect Trial” (ACTIV-5/BET) evaluating lenzilumab with remdesivir, compared to placebo and remdesivir, in patients hospitalized with COVID-19.
28 Oct 2020
Clinical Trials
Human Trials
Aurinia begins voclosporin trial in kidney transplant recipients with Covid-19

By PBR Staff Writer

Aurinia Pharmaceuticals has announced the commencement of an open-label exploratory trial to assess antiviral activity of voclosporin in kidney transplant recipients (KTRs) with Covid-19.
27 Oct 2020
Clinical Trials
Human Trials
ANA Therapeutics starts oral niclosamide trial for Covid-19 treatment

By PBR Staff Writer

Silicon Valley-based biotech start-up ANA Therapeutics has commenced a phase 2/3 clinical trial of oral niclosamide (ANA001) to treat the Covid-19 disease.

Drug Discovery

Research & Development

Superluminal Medicines secures $60m to advance rare obesity therapy

Takeda and Weave Bio collaborate on AI-driven automation in drug development

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG

Gerresheimer at CPHI Frankfurt 2025

Suppliers

No data found

Clinical Trials

TFF Pharmaceuticals, Felix Biotechnology sign LOI for collaboration, development and licence agreement

NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer

GW Pharmaceuticals initiates phase 3 study of Nabiximols for multiple sclerosis-associated spasticity

Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen

Bristol Myers Squibb’s deucravacitinib meets co-primary endpoints in psoriasis study

Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease

Humanigen announces first patient dosed in phase 3 clinical study of lenzilumab in Covid-19

Humanigen announces first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19

Aurinia begins voclosporin trial in kidney transplant recipients with Covid-19

ANA Therapeutics starts oral niclosamide trial for Covid-19 treatment

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found